Dietary Phytoestrogens as Risk Factors for Systemic Lupus Erythematosus
NCT03421184 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 63
Last updated 2026-05-14
Summary
The study aims at determining if dietary phytoestrogens can be risk factors for Systemic Lupus Erythematosus (SLE). Dietary enquiry and phytoestrogens measurements will be performed in blood and urine of patients with SLE in an active phase of the disease, in patient with other autoimmune diseases and in healthy volunteers. Subjects will be premenopausal women and when possible at a define stage of the menstrual cycle. Free blood estradiol will be assayed as a confounding risk factor.
Conditions
- Lupus Erythematosus
- Rheumatoid Arthritis
- Autoimmune Thrombocytopenia
Interventions
- OTHER
-
blood sample
25 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
- OTHER
-
urine sample
10 ml
- OTHER
-
food questionnaire
dietary habit enquiry and a 48h dietary
- OTHER
-
hair
lock of hair
Sponsors & Collaborators
-
University Hospital, Bordeaux
lead OTHER
Principal Investigators
-
Jean-François VIALLARD, Prof · University Hospital, Bordeaux
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2018-11-26
- Primary Completion
- 2023-06-26
- Completion
- 2023-06-26
Countries
- France
Study Locations
More Related Trials
-
Safety of Estrogens in Lupus: Birth Control Pills
NCT00000420 ·Status: COMPLETED ·Phase: PHASE3
-
Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention
NCT00189124 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Disease Progression and Activity in Patients With Systemic Lupus Erythematosus
NCT00339261 ·Status: COMPLETED
-
Prospective Evaluation of Decision and Compliance With Antimalarials in Patients With Systemic Lupus
NCT02364908 ·Status: COMPLETED ·Phase: NA
-
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Active Systemic Lupus Erythematosus
NCT00004662 ·Status: COMPLETED ·Phase: PHASE3
-
Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome
NCT00391924 ·Status: COMPLETED ·Phase: PHASE2
-
Longitudinal Study of Quality of Life and Activity in Systemic Lupus Erythematosus
NCT01904812 ·Status: COMPLETED ·Phase: NA
-
Pregnancies Before the Diagnosis of Systemic Lupus Erythematosus
NCT07148115 ·Status: RECRUITING
-
Gynecological Symptoms and Health-related Quality of Life in Egyptian Women With SLE
NCT05230316 ·Status: UNKNOWN
-
Study of Gynecological Follow-up of Patients With Autoimmune Disease or Inflammatory Rheumatism
NCT05961267 ·Status: COMPLETED
-
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
NCT01261793 ·Status: COMPLETED ·Phase: PHASE3
-
Immune Mediators and Metabolites to Stratify Systemic Lupus Erythematosus Patients at High Risk of Cardio Vascular Diseases
NCT04276701 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus
NCT01405196 ·Status: COMPLETED ·Phase: PHASE2
-
Pilot Study - Effect of Omega-3 on Systemic Lupus Erythematosus
NCT02021513 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus.
NCT02891213 ·Status: UNKNOWN
-
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus
NCT01262365 ·Status: COMPLETED ·Phase: PHASE3
-
Phase II Study of Long-Term Dehydroepiandrosterone for Systemic Lupus Erythematosus
NCT00004665 ·Status: COMPLETED ·Phase: PHASE2
-
Hormonal and Environmental Risk Factors for Developing Systemic Lupus Erythematosus: The Carolina Lupus (CLU) Study
NCT00342095 ·Status: COMPLETED
-
Clonal Hematopoiesis of Indeterminate Potential and Accelerated Atherosclerosis in Systemic Lupus Erythematosus
NCT05146414 ·Status: COMPLETED
-
Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients .
NCT05326841 ·Status: COMPLETED ·Phase: PHASE3
-
Psycho-social Consequences of Systemic Lupus Erythematosus
NCT03913754 ·Status: COMPLETED
-
Acceptability and Persistence of the Use of a Patient-centred E-health Tool for Lupus Patients Followed in a Specialised Centre in France
NCT03953690 ·Status: TERMINATED
-
Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis
NCT03575156 ·Status: COMPLETED ·Phase: NA
-
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
NCT07175285 ·Status: RECRUITING
-
Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus
NCT00017641 ·Status: UNKNOWN ·Phase: PHASE1